FDA approves AbbVie’s Skyrizi to treat Crohn’s Disease in adults
The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
A pre-clinical stage biotech company, Trutino Biosciences is engaged in discovering and developing next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim has a two-pronged research